Compounded semaglutide was the reason a GLP-1 could be sold for under a hundred dollars a month for two years, and it is also the reason we will say plainly, on the record: we will never prescribe one. Not at any price, not with any margin offered, not as a stopgap while branded supply tightens. Here is what compounding actually is, what changed at the FDA, and what our protocols do instead. If you are asking why we will never prescribe compounded GLP-1s while other programs still will, the answer is not a marketing preference; it is a clinical position, and we would rather you hear it before you pay us anything.
- A compounded GLP-1 is a pharmacy-made copy of a branded drug; the FDA has never reviewed it for safety, purity or dose accuracy.
- The FDA declared the semaglutide and tirzepatide shortages resolved, which ended the mass-compounding era those prices were built on.
- 18% of US adults have taken a GLP-1 and 12% are currently taking one (KFF, Nov 2025), so this is a decision affecting millions, not a niche debate.
- Our protocols are branded-only: Wegovy, Zepbound, Ozempic, Mounjaro and the oral options, prescribed only when labs support them.
- The clinician and the medication are two separate charges, and nothing in our fee structure earns more from a cheaper molecule.
The question compounded pricing raises
A question comes up whenever compounded GLP-1s are discussed, and we choose not to dodge it. Picture someone paying a program $149 a month for what arrives in a small vial with no brand name on it. The weight is coming off. The injections sting differently week to week. Nobody has drawn a single lab. The question is not 'is this safe.' It is: 'if this is the same medicine, why are you charging me more?'
It is a serious question and it deserves a serious answer, which is the one this page is. Because the honest answer is that it is not the same medicine, in ways that matter clinically and in ways that matter legally, and because the price gap has been closing anyway, in public, at the manufacturer level. What the low-price era actually proved is something else: how many people will trade a verifiable product for a plausible one when nobody sits down and explains the difference.
What compounding is, and why it exists at all
Compounding is a real and legitimate corner of pharmacy. When a patient has a documented allergy to a specific ingredient, or needs a strength no manufacturer makes, a pharmacist prepares a small, individual batch. The practice is regulated, but the rules are different from the ones for manufactured drugs: a compounded preparation does not go through the FDA's review for safety, effectiveness, purity and dose accuracy. It never has. That is not a scandal; it is the design of the system. Compounding was meant to serve a handful of patients a pharmacy personally knew.
What happened in 2023 and 2024 was not that. When brand-name semaglutide and tirzepatide appeared on the FDA's shortage list, the shortage rules opened a window: compounders could legally prepare copies of a drug that was in shortage, at scale, without individually prescribed reasons. Some compounded volumes reached numbers the practice was never designed for. The copy was labeled semaglutide. It was not the product any regulator had ever checked.
What the two products actually are
| Question | Branded, FDA-approved | Compounded copy | ||
|---|---|---|---|---|
| --- | --- | --- | ||
| FDA reviewed for safety and effectiveness | Yes, for the exact product | No | ||
| Dose accuracy verified by the agency | Yes | No | ||
| Purity and sterility standards | Manufacturing-grade | Pharmacy-grade, variable | ||
| Supply protected from one policy change | Yes | No; shortage resolution ends it | ||
| Who is accountable if something goes wrong | Manufacturer, with the FDA's authority behind it | Often a gray area |
What changed at the FDA, and why the math behind $99 fell apart
The FDA declared the semaglutide shortage resolved in early 2025 and the tirzepatide shortage shortly after, and the agency published the transition rules compounders had to follow. The door that made mass compounding legal was a shortage door, and the shortage ended. The agency's own language on the transition, including the timelines compounders had to meet, is public and worth reading directly: see the FDA's policies for compounders as GLP-1 supply stabilized.
The pricing consequence is simple. Under a hundred dollars a month was only ever possible because the active ingredient arrived in bulk with no FDA review attached to it. That ingredient stream had a regulatory clock on it from the start. Programs built on it faced a choice: convert to branded medication, exit the category, or quietly keep going and hope enforcement does not reach them. You can see which programs chose which by looking at what they advertise today.
The scale behind this is worth naming, because the people affected are not an abstraction. In KFF's national poll fielded in late October and early November 2025, 18% of US adults said they have ever taken a GLP-1 medication and 12% said they are currently taking one. A policy change of this kind reaches into millions of households. See the KFF Health Tracking Poll for the full picture.
The four reasons our protocols exclude compounded, in order of importance
One: we cannot verify the dose we are titrating. GLP-1 therapy is a dosing discipline. We increase by small steps and hold for weeks, watching response and tolerability. If the concentration in the vial is not what the label says, every one of those decisions is being made against a number that is not real. A protocol built on an unverified concentration is not a protocol; it is a guess with a schedule.
Two: the product itself was never reviewed. No regulator has looked at that specific batch and concluded it is what it claims to be, free of what it should not contain. Individual pharmacies publish their own testing, which is a start, but it is the pharmacy grading its own work.
Three: the supply is a regulatory hostage. A patient six months into a working titration should never learn from a shipping notice that their medication no longer exists. That happened, at scale, when the shortages resolved. Branded medication has its own supply risks, but it does not have a legal foundation that a single agency determination can remove.
Four: it is the wrong moment in care. Compounding flourished in a channel where nobody was looking at labs. Our model is the opposite: the Biomarker Audit first, the branded prescription second, the dose that earns its place third. A compounded copy is the artifact of a system that skipped the first two steps.
One flat fee for the doctor. Zero markup on the medicine.
What we prescribe instead, and how the money works
When the labs and the history support a GLP-1, we prescribe branded, FDA-approved medication: Wegovy, Zepbound, Ozempic or Mounjaro, and the oral options where they fit. Zepbound and Mounjaro are the same molecule, tirzepatide; which one is prescribed depends on whether weight or type 2 diabetes is the treatment target. The prescription is written to the pharmacy you choose, and the pharmacy bills you at its own price.
That is the part people sometimes misread as an upcharge hiding somewhere, so we will state it as flatly as we can: we earn nothing on the medication. Not a markup, not an affiliate fee, not a dose-based surcharge. The clinician is a $598 first charge that covers the first two months, then $299 a month, cancel anytime after. The medication is the second charge, and it belongs to the pharmacy. The structure is described plainly in Aligned Medicine and the zero-markup model, and the framing of the offer itself is in what the $299 membership actually buys.
If you are on compounded right now, what to do this week
First, do not stop abruptly and do not panic. The medication is not going to vanish overnight, and abrupt discontinuation on your own is a worse plan than a scheduled conversion. Second, gather the facts: which vials, what concentration, what dose history, what you paid. Third, take those to a clinician who will look at labs before writing anything, because the honest question is not only what to switch to but whether that medication was right for your metabolic picture in the first place. Our medical weight loss program starts exactly there, and the conversion itself is usually unremarkable when it is planned rather than forced.
FAQ
Why will GoodLife Health never prescribe compounded GLP-1s? Because a compounded copy was never FDA-reviewed for safety, purity or dose accuracy, and its legal foundation was a shortage declaration that has since ended. Our protocols require branded, FDA-approved medication only, so a supply cannot be wiped out by a single regulatory decision.
Are compounded GLP-1s illegal? Not in every case; narrow individual-patient compounding remains legitimate. What ended is mass production of copies at scale once the shortages were declared resolved.
What should I do if I am taking a compounded GLP-1 right now? Bring your vials, dose history and any labs to a clinician. Do not stop abruptly. A baseline panel comes before any conversion plan, because the first question is whether the medication was right for your metabolic picture at all.
Does the membership fee include the medication? No, and we will not blur it. Two separate charges: the clinician, flat at $299 a month after a $598 start, and the medication, billed by your pharmacy at the pharmacy's own price with nothing added by us.
What if compounded is genuinely the cheapest way to get a GLP-1? Then that price is not buying an FDA-reviewed product, a verified dose or a protected supply chain. Some apparent savings are a smaller product, not a discount on the same one.
How do I know a program will not switch me to compounded later? Ask directly whether any part of the formulary is compounded and whether they would ever substitute one for branded supply. A program that cannot say no will do it the moment economics favor it.
Sources
- FDA, "Clarifies policies for compounders as national GLP-1 supply begins to stabilize" (fda.gov)
- KFF Health Tracking Poll, October-November 2025 (kff.org)